Al-Samkari, H., Cuker, A., Zaja, F., Michel, M., Ghanima, W., Stauch, T., Zhang, L., Hou, M., Zander, T., Sharif, A., Sun, J., Nath, P. U. K., Schutgens, R., Rossi, E., Deleu, L., Červinek, L., Yoon, J., Chang, H., Ruchutrakool, T., Iino, M., Goto, T., Urban, P., Fronczek, J., Foster, M., Weill, M., Cooper, N. (2025). Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment. Blood. https://doi.org/10.1182/blood-2025-lba-2